HOME >> BIOLOGY >> NEWS
Waging war on the deadliest superbug

It infiltrates hospitals as microscopic spores. Its defences are so strong it can resist most antibiotics. And it kills three times as many people every year as MRSA. But scientists at The University of Nottingham are amassing an arsenal of weapons in preparation for counter offensive against the most deadly of hospital superbugs.

A research group led by Professor Nigel Minton in the Centre for Healthcare Associated Infections (CHAI), with Dr Peter Mullany at University College, London have been awarded over 1.6m for one of the countrys largest studies into C.difficile (C. diff). The work funded by the Medical Research Council, follows a scientific breakthrough by CHAI microbiologists that is set to revolutionise the genetic analysis of Clostridium difficile and its close relatives.

Until now scientists have understood very little about the biology of C-diff. With funding from the Biotechnology and Biological Sciences Research Council (BBSRC) and Morvus Technology Ltd, Professor Nigel Minton and his team have developed the ClosTron knock out system which can target specific genes in C. diff and other clostridial species. For the very first time scientists have an extremely rapid and effective way of identifying and deactivating the toxins and other factors that cause the disease and can begin the search for new therapies to prevent or cure it.

Professor Minton said: Although we have the entire genetic blueprint of C.diff, and have an inkling as to what bacterial factors might be important in disease, we have been unable to test these ideas. You never really know what a particular factor is doing until it isnt there. You need to be able to inactivate, knock-out, the gene responsible, and then see if the bacterium can still cause disease. Until now knocking out genes has been very difficult to do. Our breakthrough ClosTron technology now makes gene knock-out very quick and easy. Once we know what factors are important we should
'"/>

Contact: Professor Richard James
44-011-584-67952
University of Nottingham
3-Jul-2007


Page: 1 2 3

Related biology news :

1. Genome of Clostridium botulinum reveals the background to worlds deadliest toxin
2. Bridge protein spurs deadliest stages of breast cancer
3. A fisheye view of the deadliest breast cancer
4. Einstein researchers find key to unlocking worlds deadliest malaria parasite
5. Researchers report breakthrough against worlds deadliest viruses
6. Key found to kill cystic fibrosis superbug
7. UBC researchers find new superbug weapon for near-empty antibiotics arsenal
8. New antibacterials being developed to tackle MRSA superbug
9. Unusual antibiotics show promise against deadly superbugs
10. Return of the Staphylococcus aureus superbug

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... today announced the launch of the Supplyframe Design Lab . Located in ... to explore the future of how hardware projects are designed, built and brought ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... June 23, 2016 On Wednesday, June ... 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% ... at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the ... Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. ... BIND ). Learn more about these stocks by ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
Breaking Biology Technology:
Cached News: